section name header

Pronunciation

al-oh-GLIP-tin

Classifications

Therapeutic Classification: antidiabetics

Pharmacologic Classification: dipeptidyl peptidase-4 dpp-4 inhibitors

Indications

REMS


Action

  • Acts as a competitive inhibitor of dipeptidyl peptidase-4 (DPP-4) which slows the inactivation of incretin hormones, thereby increasing their concentrations and reducing fasting and postprandial glucose concentrations.
Therapeutic effects:
  • Improved control of blood glucose.

Pharmacokinetics

Absorption: Completely absorbed following oral administration (100%).

Distribution: Well distributed to tissues.

Metabolism/Excretion: Not extensively metabolized, 76% excreted unchanged in urine.

Half-Life: 21 hr.

Time/Action Profile

(inhibition of DPP-4)

ROUTEONSETPEAKDURATION
POunknown1–2 hr24 hr



Multiple dosing.



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Route/Dosage

Renal Impairment

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Nesina